MENU
+Compare
ETNB
Stock ticker: NASDAQ
AS OF
Aug 21, 03:38 PM (EDT)
Price
$9.15
Change
+$0.05 (+0.55%)
Capitalization
1.33B

ETNB 89bio Forecast, Technical & Fundamental Analysis

89bio Inc is a United States-based clinical-stage biopharmaceutical company focused on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases... Show more

ETNB
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interact to see
Advertisement
A.I.Advisor
a Summary for ETNB with price predictions
Aug 20, 2025

ETNB's MACD Histogram crosses above signal line

The Moving Average Convergence Divergence (MACD) for ETNB turned positive on August 20, 2025. Looking at past instances where ETNB's MACD turned positive, the stock continued to rise in of 45 cases over the following month. The odds of a continued upward trend are .

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where ETNB's RSI Oscillator exited the oversold zone, of 29 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are .

The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. of 59 cases where ETNB's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are .

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where ETNB advanced for three days, in of 267 cases, the price rose further within the following month. The odds of a continued upward trend are .

ETNB may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

Bearish Trend Analysis

The Momentum Indicator moved below the 0 level on August 19, 2025. You may want to consider selling the stock, shorting the stock, or exploring put options on ETNB as a result. In of 87 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .

ETNB moved below its 50-day moving average on July 28, 2025 date and that indicates a change from an upward trend to a downward trend.

The 10-day moving average for ETNB crossed bearishly below the 50-day moving average on July 30, 2025. This indicates that the trend has shifted lower and could be considered a sell signal. In of 13 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are .

Following a 3-day decline, the stock is projected to fall further. Considering past instances where ETNB declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

The Aroon Indicator for ETNB entered a downward trend on August 19, 2025. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.558) is normal, around the industry mean (19.342). P/E Ratio (0.000) is within average values for comparable stocks, (50.253). ETNB's Projected Growth (PEG Ratio) (0.000) is slightly lower than the industry average of (2.941). Dividend Yield (0.000) settles around the average of (0.043) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (299.575).

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating fairly steady price growth. ETNB’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ETNB’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock worse than average.

View a ticker or compare two or three
ETNB
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interact to see
Advertisement
A.I. Advisor
published Earnings

ETNB is expected to report earnings to fall 29.80% to -49 cents per share on November 06

89bio ETNB Stock Earnings Reports
Q3'25
Est.
$-0.50
Q2'25
Missed
by $0.21
Q1'25
Beat
by $0.03
Q4'24
Missed
by $0.27
Q3'24
Missed
by $0.77
The last earnings report on August 07 showed earnings per share of -70 cents, missing the estimate of -50 cents. With 191.04K shares outstanding, the current market capitalization sits at 1.33B.
A.I. Advisor
published General Information

General Information

a clinical-stage biopharmaceutical company, which focuses on the development and commercialization of innovative therapies for nonalcoholic steatohepatitis (NASH), liver and cardio-metabolic diseases

Industry Biotechnology

Profile
Fundamentals
Details
Industry
N/A
Address
142 Sansome Street
Phone
+1 415 432-9270
Employees
70
Web
https://www.89bio.com
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
PMCKX24.850.17
+0.69%
Victory Pioneer Mid Cap Value R6
DAGVX48.480.13
+0.27%
BNY Mellon Dynamic Value Fund A
ACWDX17.68N/A
N/A
AMG GW&K Small/Mid Cap Growth N
BDOAX11.74-0.04
-0.34%
iShares MSCI Total Intl Idx Inv A
GMRIX12.47-0.10
-0.80%
Nationwide Small Cap Index R6

ETNB and Stocks

Correlation & Price change

A.I.dvisor indicates that over the last year, ETNB has been loosely correlated with AKRO. These tickers have moved in lockstep 60% of the time. This A.I.-generated data suggests there is some statistical probability that if ETNB jumps, then AKRO could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ETNB
1D Price
Change %
ETNB100%
-4.66%
AKRO - ETNB
60%
Loosely correlated
-2.04%
IDYA - ETNB
55%
Loosely correlated
-2.83%
BEAM - ETNB
51%
Loosely correlated
-4.39%
IRON - ETNB
50%
Loosely correlated
-1.12%
SYRE - ETNB
49%
Loosely correlated
-4.90%
More